Detectability of cannabinoids in the serum samples of cannabis users: Indicators of recent cannabis use? A follow-up study.
LC-MS/MS
cannabinoids
serum
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
07
06
2021
received:
28
04
2021
accepted:
07
06
2021
pubmed:
12
6
2021
medline:
22
1
2022
entrez:
11
6
2021
Statut:
ppublish
Résumé
Forensic toxicologists are frequently required to predict the time of last cannabis consumption. Several studies suggested the utility of minor cannabinoids as indicators of recent cannabis use. Because several factors influence blood cannabinoid concentrations, the interpretation of serum cannabinoid concentrations remains challenging. To assess the informative value of serum cannabinoid levels in cannabis users (in total N = 117 patients, including 56 patients who stated an exact time of last cannabis use within 24 h before blood sampling), the detectability of cannabinoids, namely, delta-9-tetrahydrocannabinol (delta-9-THC), 11-hydroxy-delta-9-THC, 11-nor-9-carboxy-delta-9-THC, cannabichromene (CBC), cannabidiol (CBD), cannabinol (CBN), cannabidivarin, tetrahydrocannabivarin, cannabigerol (CBG), cannabicyclol, delta-8-THC, tetrahydrocannabinolic acid A, cannabichromenic acid, cannabidiolic acid (CBDA), cannabigerolic acid, cannabicyclolic acid (CBLA), 11-nor-9-carboxy-THCV (THCVCOOH), and 11-nor-CBN-9-COOH, was investigated. Excluding CBDA and CBLA, all investigated cannabinoids were detected in at least one analyzed sample. The interval between cannabis consumption and sample collection (reported by the patients) was not correlated with cannabinoid concentrations. Minor cannabinoids tended to be more easily detected in samples obtained shortly after consumption. However, some samples tested positive for minor cannabinoids despite an interval of several hours or even days between consumption and sampling (according to patients' statements). For instance, CBC, CBG, THCVCOOH, CBD, and CBN in certain cases could be detected more than 24 h after the last consumption of cannabis. Thus, findings of minor cannabinoids should always be interpreted with caution.
Substances chimiques
Cannabinoids
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1614-1626Informations de copyright
© 2021 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
Tönnes S, Auwärter V, Knoche A, Skopp G. Stand der wissenschaftlichen Erkenntnisse zur Feststellung einer mangelhaften Trennung von Cannabiskonsum und Fahren anhand der Konzentration von Tetrahydrocannabinol (THC) im Blutserum. Blutalkohol. 2016;53(6):409-414.
Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol. 2008;32(7):470-477.
Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16(5):276-282.
Huestis MA, Barnes A, Smith ML. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. Clin Chem. 2005;51(12):2289-2295.
Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of Δ9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol. 1992;16(5):283-290.
Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-1804.
Johansson E, Norén K, Sjövall J, Halldin MM. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomedical Chromatogr. 1989;3(1):35-38.
Kraemer M, Broecker S, Diehl BWK, Madea B, Hess C. Palmitic acid ester of tetrahydrocannabinol (THC) and palmitic acid diester of 11-hydroxy-THC-unsuccessful search for additional THC metabolites in human body fluids and tissues. Forensic Sci Int. 2019;294:86-95.
Schaefer N, Nordmeier F, Kröll A-K, et al. Is adipose tissue suitable for detection of (synthetic) cannabinoids? A comparative study analyzing antemortem and postmortem specimens following pulmonary administration of JWH-210, RCS-4, as well as Δ9-tetrahydrocannabinol to pigs. Arch Toxicol. 2020;94(10):3421-3431.
Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science. 1973;179(4071):391-393.
Skopp G, Pötsch L. Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking. J Anal Toxicol. 2008;32(2):160-164.
Bergamaschi MM, Karschner EL, Goodwin RS, et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem. 2013;59(3):519-526.
Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids' pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem. 2016;62(12):1579-1592.
Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem. 2014;60(4):631-643.
Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem. 2011;57(10):1406-1414.
Kraemer M, Madea B, Hess C. Detectability of various cannabinoids in plasma samples of cannabis users: Indicators of recent cannabis use? Drug Test Anal. 2019;11(10):1498-1506.
Hackett LP, Dusci LJ, Ilett KF, Chiswell GM. Optimizing the hydrolysis of codeine and morphine glucuronides in urine. Ther Drug Monit. 2002;24(5):652-657.
Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165(2-3):216-224.
Peters FT, Hartung M, Herbold M, Schmitt G, Daldrup T, Mußhoff F. Anhang B zur Richtlinie der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen: Anforderungen an die Validierung von Analysenmethoden. Toxichem Krimtech. 2009;76(3):185-208.
Elzinga S, Fischedick J, Podkolinski R, Raber JC. Cannabinoids and terpenes as chemotaxonomic markers in cannabis. Nat Prod Chem Res. 2015;3:1-9.
Ross SA, ElSohly MA. CBN and Δ9-THC concentration ratio as an indicator of the age of stored marijuana samples. Bull Narc. 1997;49(50):139-147.
Zamengo L, Bettin C, Badocco D, Di Marco V, Miolo G, Frison G. The role of time and storage conditions on the composition of hashish and marijuana samples: a four-year study. Forensic Sci Int. 2019;298:131-137.
Dussy FE, Hamberg C, Luginbühl M, Schwerzmann T, Briellmann TA. Isolation of Δ9-THCA-A from hemp and analytical aspects concerning the determination of Δ9-THC in cannabis products. Forensic Sci Int. 2005;149(1):3-10.
Scheidweiler KB, Schwope DM, Karschner EL, Desrosiers NA, Gorelick DA, Huestis MA. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. Clinical Chem. 2013;59(7):1108-1117.
European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2020. https://www.emcdda.europa.eu/system/files/publications/13236/TDAT20001ENN_web.pdf. Accessed December 17, 2020.
Potter DJ, Clark P, Brown MB. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci. 2008;53(1):90-94.
de Oliveira GL, Voloch MH, Sztulman GB, Neto ON, Yonamine M. Cannabinoid contents in cannabis products seized in São Paulo, Brazil, 2006-2007. Forensic Toxicol. 2008;26(1):31-35.
Hanuš LO, Levy R, De La Vega D, Katz L, Roman M, Tomíček P. The main cannabinoids content in hashish samples seized in Israel and Czech Republic. Isr J Plant Sci. 2016;63(3):182-190.
Burgdorf JR, Kilmer B, Pacula RL. Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend. 2011;117(1):59-61.
Stefanidou M, Dona A, Athanaselis S, Papoutsis I, Koutselinis A. The cannabinoid content of marihuana samples seized in Greece and its forensic application. Forensic Sci Int. 1998;95(2):153-162.
Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PloS One. 2013;8(7):e70052.
Raikos N, Schmid H, Nussbaumer S, et al. Determination of Δ9-tetrahydrocannabinolic acid A (Δ9-THCA-A) in whole blood and plasma by LC-MS/MS and application in authentic samples from drivers suspected of driving under the influence of cannabis. Forensic Sci Int. 2014;243:130-136.
Nadulski T, Sporkert F, Schnelle M, et al. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol. 2005;29(8):782-789.
Toennes SW, Theunissen EL, Ramaekers JG. Überprüfung der Zuverlässigkeit der “Huestis-Formeln” zur Schätzung des Cannabiskonsumzeitpunkts. Blutalkohol. 2020;57(6):321-330.
Karschner EL, Schwope DM, Schwilke EW, et al. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend. 2012;125(3):313-319.
Wang M, Wang Y-H, Avula B, et al. Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry. Cannabis Cannabinoid Res. 2016;1(1):262-271.
Meier U, Dussy F, Scheurer E, Mercer-Chalmers-Bender K, Hangartner S. Cannabinoid concentrations in blood and urine after smoking cannabidiol joints. Forensic Sci Int. 2018;291:62-67.
Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharm Exp Ther. 1990;255(2):624-630.
Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. In: Phytocannabinoids. Springer; 2017:103-131.
Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol. 1992;16(4):228-235.
Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 2006;28(2):155-163.
Daldrup T, Käferstein H, Köhler H, Maier R, Musshoff F. Entscheidung zwischen einmaligem/gelegentlichem und regelmäßigem Cannabiskonsum. Blutalkohol. 2000;37(1):39-47.
Daldrup T. Cannabiskonsum und Fahreignung-Erfahrungen und Ergebnisse aus Nordrhein-Westfalen. https://www.gtfch.org/cms/images/stories/media/tb/tb2007/s074-084.pdf. Accessed January 28, 2021.
Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral Δ9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clinical Chem. 2011;57(1):66-75.